Mifepristone and misoprostol versus misoprostol alone for uterine evacuation after early pregnancy failure: study protocol for a randomized double blinded placebo-controlled comparison (Triple M Trial)

Joyce van den Berg, Charlotte C Hamel, Marcus P Snijders, Sjors F Coppus, Frank P Vandenbussche, Joyce van den Berg, Charlotte C Hamel, Marcus P Snijders, Sjors F Coppus, Frank P Vandenbussche

Abstract

Background: Early pregnancy failure (EPF) is a common complication of pregnancy. If women do not abort spontaneously, they will undergo medical or surgical treatment in order to remove the products of conception from the uterus. Curettage, although highly effective, is associated with a risk of complications; medical treatment with misoprostol is a safe and less expensive alternative. Unfortunately, after 1 week of expectant management in case of EPF, medical treatment with misoprostol has a complete evacuation rate of approximately 50%. Misoprostol treatment results may be improved by pre-treatment with mifepristone; its effectiveness has already been proven for other indications of pregnancy termination. This study will test the hypothesis that, in EPF, the sequential combination of mifepristone with misoprostol is superior to the use of misoprostol alone in terms of complete evacuation (primary outcome), patient satisfaction, complications, side effects and costs (secondary outcomes).

Methods: The trial will be performed multi-centred, prospectively, two-armed, randomised, double-blinded and placebo-controlled. Women with confirmed EPF by ultrasonography (6-14 weeks), managed expectantly for at least 1 week, can be included and randomised to pre-treatment with oral mifepristone (600 mg) or oral placebo (identical in appearance). Randomisation will take place after receiving written consent to participate. In both arms pre-treatment will be followed by oral misoprostol, which will start 36-48 h later consisting of two doses 400 μg (4 hrs apart), repeated after 24 h if no tissue is lost. Four hundred sixty-four women will be randomised in a 1:1 ratio, stratified by centre. Ultrasonography 2 weeks after treatment will determine short term treatment effect. When the gestational sac is expulsed, expectant management is advised until 6 weeks after treatment when the definitive primary endpoint, complete or incomplete evacuation, will be determined. A sonographic endometrial thickness < 15 mm using only the allocated therapy by randomisation is considered as successful treatment. Secondary outcome measures (patient satisfaction, complications, side effects and costs) will be registered using a case report form, patient diary and validated questionnaires (Short Form 36, EuroQol-VAS, Client Satisfaction Questionnaire, iMTA Productivity Cost Questionnaire).

Discussion: This trial will answer the question if, in case of EPF, after at least 1 week of expectant management, sequential treatment with mifepristone and misoprostol is more effective than misoprostol alone to achieve complete evacuation of the products of conception.

Trial registration: Clinicaltrials.gov (d.d. 02-07-2017): NCT03212352. Trialregister.nl (d.d. 03-07-2017): NTR6550. EudraCT number (d.d. 07-08-2017): 2017-002694-19. File number Commisie Mensgebonden Onderzoek (d.d. 07-08-2017): NL 62449.091.17.

Keywords: Early pregnancy failure; Mifepristone; Miscarriage; Misoprostol; Missed abortion.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flowchart of study procedures. *If no tissue is lost by day four, two more doses of misoprostol will be taken at day four

References

    1. Open data van de Nederlandse Zorgautoriteit (2014-2016) [].
    1. Graziosi GC, Mol BW, Reuwer PJ, Drogtrop A, Bruinse HW. Misoprostol versus curettage in women with early pregnancy failure after initial expectant management: a randomized trial. Hum Reprod. 2004;19(8):1894–1899. doi: 10.1093/humrep/deh344.
    1. You JH, Chung TK. Expectant, medical or surgical treatment for spontaneous abortion in first trimester of pregnancy: a cost analysis. Hum Reprod. 2005;20(10):2873–2878. doi: 10.1093/humrep/dei163.
    1. Hooker AB, Lemmers M, Thurkow AL, Heymans MW, Opmeer BC, Brolmann HA, Mol BW, Huirne JA. Systematic review and meta-analysis of intrauterine adhesions after miscarriage: prevalence, risk factors and long-term reproductive outcome. Hum Reprod Update. 2013.
    1. Lemmers M, Verschoor MA, Hooker AB, Opmeer BC, Limpens J, Huirne JA, Ankum WM, Mol BW. Dilatation and curettage increases the risk of subsequent preterm birth: a systematic review and meta-analysis. Hum Reprod. 2016;31(1):34–45. doi: 10.1093/humrep/dev274.
    1. Soulat C, Gelly M. Immediate complications of surgical abortion. J Gynecol Obstet Biol Reprod (Paris) 2006;35(2):157–162. doi: 10.1016/S0368-2315(06)76389-X.
    1. Niinimaki M, Jouppila P, Martikainen H, Talvensaari-Mattila A. A randomized study comparing efficacy and patient satisfaction in medical or surgical treatment of miscarriage. Fertil Steril. 2006;86(2):367–372. doi: 10.1016/j.fertnstert.2005.12.072.
    1. Hinshaw K, Fayyad A, Munjuluri P: The management of early pregnancy loss. Royal College of Obstetricians and Gynaecologists, Green-top Guideline No. 25. . In.; 2006.
    1. ACOG The American College of Obstetricians and Gynecologists practice bulletin no. 150. Early pregnancy loss. Obstet Gynecol. 2015;125(5):1258–1267. doi: 10.1097/01.AOG.0000465191.27155.25.
    1. Cytotec UK SPC (Summary of Product Characteristics). [].
    1. Neilson JP, Hickey M, Vazquez J. Medical treatment for early fetal death (less than 24 weeks). Cochrane Database Syst Rev. 2009;(3):CD002253.
    1. Misoprostol Recommendations. [].
    1. Luise C, Jermy K, May C, Costello G, Collins WP, Bourne TH. Outcome of expectant management of spontaneous first trimester miscarriage: observational study. BMJ. 2002;324(7342):873–875. doi: 10.1136/bmj.324.7342.873.
    1. van den Berg J, Gordon BB, Snijders MP, Vandenbussche FP, Coppus SF. The added value of mifepristone to non-surgical treatment regimens for uterine evacuation in case of early pregnancy failure: a systematic review of the literature. Eur J Obstet Gynecol Reprod Biol. 2015;195:18–26. doi: 10.1016/j.ejogrb.2015.09.027.
    1. Lemmers M, Verschoor MA, Oude Rengerink K, Naaktgeboren C, Bossuyt PM, Huirne JA, Janssen IA, Radder C, Klinkert ER, Langenveld J, et al. MisoREST: surgical versus expectant management in women with an incomplete evacuation of the uterus after misoprostol treatment for miscarriage: a cohort study. Eur J Obstet Gynecol Reprod Biol. 2017;211:83–89. doi: 10.1016/j.ejogrb.2017.01.019.
    1. Lemmers M, Verschoor MA, Oude Rengerink K, Naaktgeboren C, Opmeer BC, Bossuyt PM, Huirne JA, Janssen CA, Radder C, Klinkert ER, et al. MisoREST: surgical versus expectant management in women with an incomplete evacuation of the uterus after misoprostol treatment for miscarriage: a randomized controlled trial. Hum Reprod. 2016;31(11):2421–2427. doi: 10.1093/humrep/dew221.
    1. Mifegyne 200 mg tablets: Summary of Product Characeteristics (SmPC) [].
    1. Mifepriston [].
    1. Say L, Kulier R, Gulmezoglu M, Campana A: Medical versus surgical methods for first trimester termination of pregnancy. Cochrane Database Syst Rev 2005(1):CD003037.
    1. Kulier R, Gulmezoglu AM, Hofmeyr GJ, Cheng LN, Campana A: Medical methods for first trimester abortion. Cochrane Database Syst Rev 2008(2):CD002855.
    1. van den Berg J, van den Bent JM, Snijders MP, de Heus R, Coppus SF, Vandenbussche FP. Sequential use of mifepristone and misoprostol in treatment of early pregnancy failure appears more effective than misoprostol alone: a retrospective study. Eur J Obstet Gynecol Reprod Biol. 2014;183:16–19. doi: 10.1016/j.ejogrb.2014.10.010.
    1. Stockheim D, Machtinger R, Wiser A, Dulitzky M, Soriano D, Goldenberg M, Schiff E, Seidman DS. A randomized prospective study of misoprostol or mifepristone followed by misoprostol when needed for the treatment of women with early pregnancy failure. Fertil Steril. 2006;86(4):956–960. doi: 10.1016/j.fertnstert.2006.03.032.
    1. Wagaarachchi PT, Ashok PW, Narvekar N, Smith NC, Templeton A. Medical management of early fetal demise using a combination of mifepristone and misoprostol. Hum Reprod. 2001;16(9):1849–1853. doi: 10.1093/humrep/16.9.1849.
    1. Gronlund A, Gronlund L, Clevin L, Andersen B, Palmgren N, Lidegaard O. Management of missed abortion: comparison of medical treatment with either mifepristone + misoprostol or misoprostol alone with surgical evacuation. A multi-center trial in Copenhagen county, Denmark. Acta Obstet Gynecol Scand. 2002;81(11):1060–1065. doi: 10.1034/j.1600-0412.2002.811111.x.
    1. Coughlin LB, Roberts D, Haddad NG, Long A. Medical management of first trimester miscarriage (blighted ovum and missed abortion): is it effective? J Obstet Gynaecol. 2004;24(1):69–71. doi: 10.1080/01443610310001620332.
    1. Schreiber CA, Creinin MD, Reeves MF, Harwood BJ. Mifepristone and misoprostol for the treatment of early pregnancy failure: a pilot clinical trial. Contraception. 2006;74(6):458–462. doi: 10.1016/j.contraception.2006.07.007.
    1. Kollitz KM, Meyn LA, Lohr PA, Creinin MD. Mifepristone and misoprostol for early pregnancy failure: a cohort analysis. Am J Obstet Gynecol. 2011;204(5):386 e381–386 e386. doi: 10.1016/j.ajog.2010.12.026.
    1. Torre A, Huchon C, Bussieres L, Machevin E, Camus E, Fauconnier A. Immediate versus delayed medical treatment for first-trimester miscarriage: a randomized trial. Am J Obstet Gynecol. 2012;206(3):215 e211–215 e216. doi: 10.1016/j.ajog.2011.12.009.
    1. Van den Berg J, Snijders MP, Coppus SF, Vandenbussche FP: Mifepristone followed by misoprostol for uterine evacuation in early pregnancy failure: a randomized, double blinded, placebo controlled pilot study. Submitted. In.; 2017.
    1. In: Clinical Practice Handbook for Safe Abortion. Edn. Geneva; 2014.
    1. Maria B, Chaneac M, Stampf F, Ulmann A. Early pregnancy interruption using an antiprogesterone steroid: mifepristone (RU 486) J Gynecol Obstet Biol Reprod (Paris) 1988;17(8):1089–1094.
    1. Grimes DA, Mishell DR, Jr, Shoupe D, Lacarra M. Early abortion with a single dose of the antiprogestin RU-486. Am J Obstet Gynecol. 1988;158(6):1307–1312. doi: 10.1016/0002-9378(88)90361-4.
    1. Saurel-Cubizolles MJ, Opatowski M, David P, Bardy F, Dunbavand A. Pain during medical abortion: a multicenter study in France. Eur J Obstet Gynecol Reprod Biol. 2015;194:212–217. doi: 10.1016/j.ejogrb.2015.09.025.
    1. Verschoor MA, Lemmers M, Wekker MZ, Huirne JA, Goddijn M, Mol BW, Ankum WM. Practice variation in the management of first trimester miscarriage in the Netherlands: a nationwide survey. Obstet Gynecol Int. 2014;2014:387860. doi: 10.1155/2014/387860.
    1. Chen BA, Creinin MD. Medical management of early pregnancy failure: efficacy. Semin Reprod Med. 2008;26(5):411–422. doi: 10.1055/s-0028-1087107.
    1. Doggrell SA: Misoprostol for the treatment of early pregnancy failure. Curr Clin Pharmacol 2007, 2(1):1–9.
    1. Fjerstad M, Trussell J, Sivin I, Lichtenberg ES, Cullins V. Rates of serious infection after changes in regimens for medical abortion. N Engl J Med. 2009;361(2):145–151. doi: 10.1056/NEJMoa0809146.
    1. Allen R, O'Brien BM. Uses of misoprostol in obstetrics and gynecology. Rev Obstet Gynecol. 2009;2(3):159–168.
    1. Marwah S, Gupta S, Batra NP, Bhasin V, Sarna V, Kaur N. A comparative study to evaluate the efficacy of vaginal vs Oral prostaglandin E1 analogue (misoprostol) in management of first trimester missed abortion. J Clin Diagn Res. 2016;10(5):QC14–QC18.
    1. Ngoc NT, Blum J, Westheimer E, Quan TT, Winikoff B. Medical treatment of missed abortion using misoprostol. Int J Gynaecol Obstet. 2004;87(2):138–142. doi: 10.1016/j.ijgo.2004.07.015.
    1. Alfirevic Z, Weeks A: Oral misoprostol for induction of labour. Cochrane Database Syst Rev 2006(2):CD001338.
    1. Ho PC, Ngai SW, Liu KL, Wong GC, Lee SW. Vaginal misoprostol compared with oral misoprostol in termination of second-trimester pregnancy. Obstet Gynecol. 1997;90(5):735–738. doi: 10.1016/S0029-7844(97)00419-5.
    1. Misoprostol as a single agent for medical termination of pregnancy [].
    1. Kim C, Barnard S, Neilson JP, Hickey M, Vazquez JC, Dou L. Medical treatments for incomplete miscarriage. Cochrane Database Syst Rev. 2017;(1):CD007223.
    1. Debby A, Golan A, Sadan O, Rotmensch S, Malinger G. Sonographic characteristics of the uterine cavity following first-trimester uterine evacuation. Ultrasound Obstet Gynecol. 2008;31(5):555–559. doi: 10.1002/uog.5274.
    1. Rulin MC, Bornstein SG, Campbell JD. The reliability of ultrasonography in the management of spontaneous abortion, clinically thought to be complete: a prospective study. Am J Obstet Gynecol. 1993;168(1):12–15. doi: 10.1016/S0002-9378(12)90877-7.
    1. Lavecchia M, Klam S, Abenhaim HA. Effect of uterine cavity sonographic measurements on medical management failure in women with early pregnancy loss. J Ultrasound Med. 2016;35(8):1705–1710. doi: 10.7863/ultra.15.09063.
    1. Creinin MD, Harwood B, Guido RS, Fox MC, Zhang J, Trial NMEPF. Endometrial thickness after misoprostol use for early pregnancy failure. Int J Gynaecol Obstet. 2004;86(1):22–26. doi: 10.1016/j.ijgo.2004.02.004.
    1. Erytrocytenimmunisatie en zwangerschap. Versie 2.1, 2009. [].
    1. Chung TK, Cheung LP, Sahota DS, Haines CJ, Chang AM. Evaluation of the accuracy of transvaginal sonography for the assessment of retained products of conception after spontaneous abortion. Gynecol Obstet Investig. 1998;45(3):190–193. doi: 10.1159/000009954.
    1. Jauniaux E, Johns J, Burton GJ. The role of ultrasound imaging in diagnosing and investigating early pregnancy failure. Ultrasound Obstet Gynecol. 2005;25(6):613–624. doi: 10.1002/uog.1892.
    1. Wildschut H, Both MI, Medema S, Thomee E, Wildhagen MF, Kapp N. Medical methods for mid-trimester termination of pregnancy. Cochrane Database Syst Rev. (2011, 1):CD005216.
    1. Hapangama D, Neilson JP. Mifepristone for induction of labour. Cochrane Database Syst Rev. 2009;3:CD002865.
    1. Schreiber CA, Creinin MD, Atrio J, Sonalkar S, Ratcliffe SJ, Barnhart KT. Mifepristone pretreatment for the medical Management of Early Pregnancy Loss. N Engl J Med. 2018;378(23):2161–2170. doi: 10.1056/NEJMoa1715726.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅